Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)
Intimation of Resignation of Mr. Arindam Haldar as Chief Executive Officer08-04-2021
08-04-2021
Thyrocare Technologies Ltd - 539871 - Intimation Under Regulation No. 30 & 36 Of SEBI For Business Update.
Update about the current business development for information of the shareholders, investors and general public..07-04-2021
Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
This is to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with effect from April 01, 2021, and would be re-opened after 48 hours of date of announcement / declaration of Audited Financial Results for the Year ended March 31, 2021. We request you to please take the same on record.31-03-2021
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the representatives of First State Sentier would be having a Con-call (Zoom) with us, at 09.00 A.M. on Monday, March 08, 2021. Please note that this is subject to any last minute changes.06-03-2021
Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Arisaig Asia Consumer Fund Limited, Arisaig Next Generation Master Fund ICAV , Segregated Mandate Account - J.P. Morgan Alternative Asset Management Inc., Segregated Mandate Account - Mercer QIF Fund PLC22-02-2021
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are filing herewith the transcript of the Earnings Call held on Thursday, February 04, 2021 at 05.00 P.M. local time, post declaration of the Company's unaudited financial results (Stand-alone and Consolidated) for Quarter / Nine Months ended December 31, 2020. This transcript is also made available at our website. Dr. A. Velumani, Chairman & Managing Director, Mr. Arindam Haldar, CEO, Mr. A. Sundararaju, CFO & Executive Director, Mr. Sachin Salvi, Vice-President- Finance, represented the Company.20-02-2021
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representatives of following organizations would be having a con-call with us; i) Mirabilis Investment Trust, at 05.00 P.M. on Monday, February 15, 2021. ii) Arisaig Partners, at 03.00 P.M. on Friday, February 19, 2021. Please note that these are subject to any last minute changes.13-02-2021
Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gordon Yeo05-02-2021
Earnings Call for Q3FY21 of Thyrocare Technologies
Conference Call with Thyrocare Technologies Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.05-02-2021
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company's financial results for Quarter / Nine Months ended December 31, 2020, on Thursday, February 04, 2021 at 05.00 P.M. local time. Dr. A. Velumani, Chairman & Managing Director, Mr. Arindam Haldar, Chief Executive Officer, Mr. A. Sundararaju, Executive Director & CFO and Mr. Sachin Salvi, Vice-President- Finance, will represent the Company. Dial-in details are given in the copy of enclosed Invite of M/s. Nomura Financial Advisory & Securities (India) Pvt. Ltd., who are organizing the con-call.03-02-2021